Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: August 19, 2024
Subject: Update on Share Repurchase Programme
Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 69,000 people across 80 countries. This filing reports on the execution of a share repurchase programme initiated on August 7, 2024, under the EU Market Abuse Regulation (MAR) "Safe Harbour Rules."
Key Financial Metrics and Transaction Details
Share Repurchase Programme Overview:
- Total Programme Cap: Up to DKK 20 billion over a 12-month period beginning February 6, 2024.
- Current Sub-Programme (Aug 7 - Nov 4, 2024): Up to DKK 2.4 billion.
Transactions Reported (August 12 - 16, 2024):
| Date | Number of B Shares | Avg. Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| Aug 12, 2024 | 40,953 | 901.93 | 36,936,779 |
| Aug 13, 2024 | 41,000 | 897.60 | 36,801,784 |
| Aug 14, 2024 | 41,000 | 904.21 | 37,072,721 |
| Aug 15, 2024 | 40,984 | 919.71 | 37,693,367 |
| Aug 16, 2024 | 41,000 | 919.68 | 37,707,059 |
| Accumulated (Current Sub-Programme) | 335,187 | - | 298,612,988 |
Cumulative Programme Status (Since Feb 6, 2024):
- Total Shares Repurchased: 11,402,313 B shares.
- Average Share Price: DKK 879.32.
- Total Transaction Value: DKK 10,026,319,038.
- Treasury Shares Held: 12,730,944 B shares (0.3% of share capital).
Other Financial Data: The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period.
Material Changes and Unusual Items
Incentive Programme Transfers: Transactions related to incentive programmes resulted in a net transfer of 14,129 B shares from the company between August 12 and August 16, 2024. These shares were explicitly excluded from the Safe Harbour repurchase programme.
Share Capital: The total number of A and B shares, including treasury shares, stands at 4,465,000,000.
Guidance, Outlook, and Management Commentary
Repurchase Outlook: Management expects to continue repurchasing B shares up to the total cap of DKK 20 billion during the 12-month period commencing February 6, 2024. As of August 16, 2024, approximately 50% of the total programme value has been executed.
Strategic Context: The company reaffirms its purpose to drive change to defeat serious chronic diseases, leveraging its heritage in diabetes and expanding access to medicines globally.
Risks and Contingencies: No specific risks or contingencies were detailed in this filing beyond the standard regulatory compliance with MAR and Safe Harbour Rules.
Key Facts for Investor Verification
- Programme Progress: Verify the remaining capacity of the DKK 20 billion programme (approx. DKK 9.97 billion remaining as of Aug 16).
- Treasury Holdings: Confirm the 0.3% ownership stake held in treasury shares and its impact on earnings per share calculations.
- Excluded Transactions: Distinguish between shares repurchased under the Safe Harbour programme and those transferred via incentive programmes.
- Market Data: Cross-reference the reported average purchase prices (ranging from DKK 897.60 to 919.71 in the latest week) with market closing prices for Novo Nordisk B shares (Novo-B) on Nasdaq Copenhagen.